Journals / Kafkas Üniversitesi Veteriner Fakültesi Dergisi / 2018 / Cilt: 24 - Sayı: 4

The Efficacy of Alone or Combined Treatment of Aglepristone and Cabergoline on Termination of Mid-term Pregnancy in Cats

Kedilerde Orta Dönem Gebeliklerin Sonlandırılmasında Aglepriston ve Cabergolinin Tek Başlarına veya Birlikte Uygulanmasının Etkinliği

Pages
491–496
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, the completion of pregnancy termination rate was 85.7% because of fetal retention in one cat from the AGL+CBG group.The interval between treatment-start of abortion (T-SA) was shorter in the AGL+CBG group (3.6±0.3 days) than in the AGL (6.5±0.0) and CBG(6.2±0.2) groups (P

📌 3 Key Takeaways

🎯
Objective & Hypothesis:This study determined the efficacy of a combination of aglepristone and cabergoline on termination of mid-term cat pregnancies.
📊
Key Findings & Data:Twenty cats withunwanted pregnancies between 30-40 days were included in the study.
💡
Conclusion & Impact:However, the completion of pregnancy termination rate was 85.7% because of fetal retention in one cat from the AGL+CBG group.The interval between treatment-start of abortion (T-SA) was shorter in the AGL+CBG group (3.6±0.3 days) than in the AGL (6.5±0.0) and CBG(6.2±0.2) groups (P
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

This study determined the efficacy of a combination of aglepristone and cabergoline on termination of mid-term cat pregnancies. Twenty cats withunwanted pregnancies between 30-40 days were included in the study. Aglepristone (10 mg/kg, sc) was given to the AGL group (n=6) twice in a24-h interval. Cabergoline (5 μg/kg, peros) was administered to the CBG group (n=7) once daily until abortion started or for 8 days. AGL+CBG (n=7)received a combined treatment with both drugs. Abortion occurred in 50% of cats in the AGL group, 71.4% in the CBG group, and 100% in theAGL+CBG. However, the completion of pregnancy termination rate was 85.7% because of fetal retention in one cat from the AGL+CBG group.The interval between treatment-start of abortion (T-SA) was shorter in the AGL+CBG group (3.6±0.3 days) than in the AGL (6.5±0.0) and CBG(6.2±0.2) groups (P

Özet

Bu çalışmada kedilerde orta dönem gebeliklerin sonlandırılmasında aglepriston ve cabergolin kombinasyonunun etkinliği belirlendi. Çalışmada istenmeyen gebeliği olan ve gebeliğin 30-40. günleri arasında olan 20 kedi kullanıldı. AGL grubuna (n=6) aglepriston (10 mg/kg, sc) 24 saat arayla iki defa uygulandı. CBG grubuna (n=7) cabergolin (5 μg/kg, peros) abortuslar başlayana kadar veya 8 gün süreyle günlük olarak uygulandı. AGL+CBG (n=7) grubuna ise her iki ilaç birlikte verildi. AGL grubunda kedilerin %50’sinde, CBG grubunda %71.4’ünde ve AGL+CBG grubunda ise %100’ünde abortuslar şekillendi. Bununla birlikte AGL+CBG grubundaki bir kedide fetal retensiyondan dolayı gebelik sonlanma oranı %85.7 olarak şekillendi. Tedavi-abortus başlama aralığı (T-SA) AGL+CBG grubunda (3.6±0.3 gün) AGL (6.5±0.0) ve CBG (6.2±0.2) gruplarından daha kısa bulundu (P

🔖

Cite This Article

FINDIK, M., KAYA, D., AY, S. S., ÖNYAY, F., SARAL, G., ASLAN, S. (2022). The Efficacy of Alone or Combined Treatment of Aglepristone and Cabergoline on Termination of Mid-term Pregnancy in Cats. Kafkas Üniversitesi Veteriner Fakültesi Dergisi, Cilt: 24 - Sayı: 4, 491–496. https://ajindex.com/articles/569921

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Vatan Ö, Bagdas D, Cinkilic N, Wehrend A, Özalp GR: Genotoxic and cytotoxic effects of the aglepristone, a progesteron antagonist, in mid-gestation pregnancy termination in rabbits. Kafkas Univ Vet Fak Derg, 21 (2): 241-246, 2015. DOI: 10.9775/kvfd.2014.12210 Onclin K, Silva LD, Donnay I, Verstegen JP: Luteotrophic action of prolactin in dogs and the effects of a dopamine agonist, cabergoline. J Reprod Fertil Suppl, 47, 403-409, 1993.
  2. Johnson SD, Kustritz MVR, Olson PNS: Feline parturition. In, Canine and Feline Theriogenology. 431-437,
  3. Saunders, Philadelphia, 2001.
  4. Agaoglu AR, Aslan S, Emre B, Korkmaz O, Ozdemir Salci ES, Kocamuftuoglu M, Seyrek-Intas K, Schafer-Somi S: Clinical evaluation of different applications of misoprostol and aglepristone for induction of abortion in bitches. Theriogenology, 81 (7): 947-951, 2014. DOI: 10.1016/j. theriogenology.2014.01.017 Fiéni F TD, Bruyas JF, Badinand F, Berhelot X, Ronsin P, Racihal L, Lefay MP: E’tude clinique d’une antihormone pour provoquer l’avortement chez la chienne: l’aglépristone. Rec Med Vet, 172, 359-367, 1996.
  5. Gorlinger S, Kooistra HS, van den Broek A, Okkens AC: Treatment of fibroadenomatous hyperplasia in cats with aglepristone. J Vet Intern Med, 16 (6): 710-713, 2002. DOI: 10.1111/J.1939-1676.2002.tb02412.x Fiéni FBJ, Tainturier D: Interruption de la gestation chez la chatte par administration d’Alizine. Vet Repro, 1, 11, 2000.
  6. Zambelli D, Castagnetti C, Belluzzi S, Bassi S: Correlation between the age of the conceptus and various ultrasonographic measurements during the first 30 days of pregnancy in domestic cats (Felis catus). Theriogenology, 57 (8): 1981-1987, 2002. DOI: 10.1016/S0093- 691X(01)00686-0
  7. Onclin K, Verstegen J: Termination of pregnancy in cats using a combination of cabergoline, a new dopamine agonist, and a synthetic PGF2 alpha, cloprostenol. J Reprod Fertil Suppl, 51, 259-263, 1997.
  8. Verstegen JP, Onclin K, Silva LD, Donnay I: Abortion induction in the cat using prostaglandin F2 alpha and a new anti-prolactinic agent, cabergoline. J Reprod Fertil Suppl, 47, 411-417, 1993.
  9. Kaya D, Kucukaslan I, Agaoglu AR, Ay SS, Schafer-Somi S, Emre B, Bal Y, Einspanier A, Gurcan IS, Gultiken N, Aslan S: The effects of aglepristone alone and in combination with cloprostenol on hormonal values during termination of mid-term pregnancy in bitches. Anim Reprod Sci, 146 (3-4): 210-217, 2014. DOI: 10.1016/j.anireprosci.2014.03.002 Agaoglu AR, Schafer-Somi S, Kaya D, Kucukaslan I, Emre B, Gultiken N, Mu